ADMA - ADMA Biologics Inc Stock Price, Fair Value and News

6.17USD+0.19 (+3.18%)Delayed as of 16 Apr 2024, 01:01 pm ET

Market Summary

USD6.17+0.19

Delayedas of 16 Apr 2024, 01:01 pm

3.18%

ADMA Alerts

1 major insider sales recently.

ADMA Stock Price

View Fullscreen

ADMA RSI Chart

ADMA Valuation

Market Cap

1.4B

Price/Earnings (Trailing)

-48.33

Price/Sales (Trailing)

5.29

EV/EBITDA

74.67

Price/Free Cashflow

338.73

ADMA Price/Sales (Trailing)

ADMA Profitability

Operating Margin

34.44%

EBT Margin

-6.96%

Return on Equity

-20.89%

Return on Assets

-8.58%

Free Cashflow Yield

0.3%

ADMA Fundamentals

ADMA Revenue

Revenue (TTM)

258.2M

Rev. Growth (Yr)

47.86%

Rev. Growth (Qtr)

9.85%

ADMA Earnings

Earnings (TTM)

-28.2M

Earnings Growth (Yr)

-44.25%

Earnings Growth (Qtr)

-787.88%

Breaking Down ADMA Revenue

52 Week Range

3.246.18

(Low)(High)

Last 7 days

-3.9%

Last 30 days

-0.2%

Last 90 days

21.3%

Trailing 12 Months

88.1%

How does ADMA drawdown profile look like?

ADMA Financial Health

Current Ratio

5.16

ADMA Investor Care

Shares Dilution (1Y)

14.83%

Diluted EPS (TTM)

-0.13

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	181.9M	208.1M	234.3M	258.2M
2022	122.6M	138.7M	159.1M	154.1M
2021	48.1M	58.1M	68.5M	109.6M
2020	36.2M	37.0M	40.1M	42.2M
2019	16.5M	18.8M	21.8M	29.6M
2018	24.2M	25.4M	24.9M	17.0M
2017	11.2M	12.3M	14.1M	22.8M
2016	7.8M	8.8M	9.8M	10.7M
2015	5.9M	5.7M	6.2M	7.2M
2014	3.8M	4.6M	4.9M	5.9M
2013	1.9M	2.4M	3.2M	3.1M
2012	1.7M	1.5M	1.3M	1.1M
2011	0	0	0	1.9M
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of ADMA Biologics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	kestenberg-messina kaitlin m.	acquired	-	-	192,320	coo and svp, compliance
Mar 31, 2024	kestenberg-messina kaitlin m.	sold (taxes)	-13,761	6.6	-2,085	coo and svp, compliance
Mar 31, 2024	grossman adam s	sold (taxes)	-143,563	6.6	-21,752	president,ceo, and interim cfo
Mar 19, 2024	elms steve	sold	-2,503,920	6.08	-411,829	-
Mar 18, 2024	elms steve	sold	-299,821	6.01	-49,887	-
Mar 15, 2024	elms steve	sold	-1,099,880	6.01	-183,008	-
Mar 14, 2024	elms steve	sold	-2,712,070	6.05	-448,276	-
Mar 13, 2024	elms steve	sold	-2,527,470	6.21	-407,000	-
Mar 07, 2024	grossman adam s	sold (taxes)	-177,180	6.16	-28,763	president and ceo
Mar 07, 2024	lenz brian	sold (taxes)	-104,504	6.16	-16,965	evp, cfo

Which funds bought or sold ADMA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 12, 2024	Game Plan Financial Advisors, LLC	unchanged	-	2,080	6,600	-%
Apr 12, 2024	AdvisorNet Financial, Inc	unchanged	-	1,040	3,300	-%
Apr 12, 2024	INSPIRION WEALTH ADVISORS, LLC	unchanged	-	24,600	79,200	0.01%
Apr 10, 2024	EWG Elevate Inc.	added	100	434,000	660,000	0.25%
Apr 09, 2024	MASSMUTUAL TRUST CO FSB/ADV	new	-	231	231	-%
Apr 09, 2024	ADIRONDACK TRUST CO	unchanged	-	726	3,861	-%
Apr 05, 2024	CWM, LLC	added	1,507	24,000	25,000	-%
Apr 05, 2024	FIRST HAWAIIAN BANK	reduced	-22.1	97,372	805,299	0.03%
Apr 05, 2024	GAMMA Investing LLC	added	231	2,487	3,260	-%
Apr 05, 2024	Prism Advisors, Inc.	new	-	128,066	128,066	0.04%

Are Funds Buying or Selling ADMA?

Are funds buying ADMA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ADMA

No. of Funds

ADMA Alerts

1 major insider sales recently.

Unveiling ADMA Biologics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 11, 2024	teachers advisors, llc	2.17%	4,955,411	SC 13G/A
Mar 11, 2024	tiaa cref investment management llc	2.17%	4,955,411	SC 13G/A
Mar 11, 2024	nuveen asset management, llc	2.17%	4,955,411	SC 13G/A
Feb 14, 2024	nuveen asset management, llc	2.24%	5,062,545	SC 13G
Feb 14, 2024	teachers advisors, llc	2.24%	5,062,545	SC 13G
Feb 14, 2024	tiaa cref investment management llc	2.24%	5,062,545	SC 13G
Feb 14, 2024	perceptive advisors llc	2.8%	6,433,369	SC 13G/A
Feb 13, 2024	vanguard group inc	5.71%	12,891,875	SC 13G
Jan 26, 2024	blackrock inc.	7.9%	17,917,745	SC 13G/A
Feb 14, 2023	nuveen asset management, llc	2.48%	5,483,369	SC 13G/A

Recent SEC filings of ADMA Biologics Inc

View All Filings

Date Filed	Form Type	Document
Apr 15, 2024	ARS	ARS
Apr 15, 2024	DEF 14A	DEF 14A
Apr 15, 2024	DEFA14A	DEFA14A
Apr 02, 2024	3	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	8-K	Current Report
Mar 19, 2024	4	Insider Trading
Mar 15, 2024	4	Insider Trading
Mar 13, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to ADMA Biologics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.7B	6.8B	0.01%	-33.89%	-8.42	5.79	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.06%	-27.57%	-42.25	10.17	76.23%	61.08%
BMRN	17.3B	2.4B	9.12%	-7.56%	103	7.14	15.42%	18.43%
INCY	12.0B	3.7B	-8.48%	-28.30%	20.07	3.25	8.87%	75.42%
MID-CAP
APLS	6.2B	396.6M	-9.27%	-36.41%	-11.74	15.65	425.83%	18.94%
BBIO	4.5B	-	-6.46%	74.90%	-6.94	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-9.62%	-0.34%	-13.52	11.95	440.80%	-27.84%
ARWR	3.0B	240.7M	-15.06%	-21.14%	-10.03	12.36	-1.03%	-92.09%
ACAD	2.8B	726.4M	-8.60%	-6.11%	-45.41	3.83	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.17%	-12.95%	25.42	4.56	85.90%	-14.05%
NVAX	576.6M	983.7M	-22.12%	-55.02%	-1.06	0.59	-50.36%	17.16%
CRBP	448.6M	881.7K	-2.13%	345.78%	-10.06	466.16	-77.61%	-5.33%
INO	256.8M	4.9M	2.33%	7.75%	-1.9	52.78	-54.97%	51.72%
IBIO	6.7M	2.1M	82.86%	81.13%	-0.25	2.14	-13.45%	66.37%

ADMA Biologics Inc News

Latest updates

ADMA Biologics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	9.9%	73,904	67,275	60,123	56,914	49,982	41,090	33,905	29,103	55,000	20,681	17,831	16,049	13,956	10,276	7,788	10,200	11,818	7,223	7,000	3,529	4,056
Cost Of Revenue	0.5%	42,817	42,622	43,433	40,401	35,805	31,433	26,136	25,441	22,872	20,295	18,833	17,770	19,111	11,855	13,496	16,829	11,692	7,916	10,491	9,405	11,142
Gross Profit	26.1%	31,086	24,653	16,690	16,513	14,177	9,657	7,769	3,662	3,511	385	-1,002	-1,721	-	-	-	-	-	-	-	-	-
Operating Expenses	5.5%	16,853	15,967	17,163	17,326	20,235	18,973	16,944	18,477	16,703	14,822	14,579	13,443	-30,115	24,077	24,911	26,970	19,864	16,273	17,900	16,737	20,604
S&GA Expenses	5.5%	15,535	14,726	14,248	14,512	13,895	12,893	11,970	13,700	11,698	10,727	10,438	10,034	9,300	9,116	8,703	7,932	7,032	7,197	6,086	5,595	6,073
R&D Expenses	-25.2%	445	596	1,403	855	1,075	1,042	873	624	729	771	1,159	988	1,013	1,708	1,656	1,529	465	491	517	871	917
EBITDA Margin	-5.3%	0.06*	0.06*	0.07*	0.06*	0.05*	0.04*	0.02*	0.01*	0.01*	0.00*	-0.01*	-0.02*	-0.05*	-	-	-	-	-	-	-	-
Interest Expenses	-2.9%	6,215	6,398	6,299	6,115	5,737	5,580	4,573	3,389	3,316	3,299	3,247	3,196	3,109	3,091	3,067	2,717	2,731	2,649	2,073	1,541	1,438
EBT Margin	9.3%	-0.07*	-0.08*	-0.09*	-0.10*	-0.12*	-0.11*	-0.13*	-0.15*	-0.16*	-0.26*	-0.31*	-0.37*	-0.43*	-	-	-	-	-	-	-	-
Net Income	-787.9%	-17,644	2,565	-6,370	-6,788	-12,231	-14,899	-13,764	-25,007	-16,649	-17,712	-18,905	-18,379	-19,407	-16,917	-20,178	-19,245	-10,561	-11,438	-13,211	-13,067	-18,037
Net Income Margin	-12.3%	-0.11*	-0.10*	-0.19*	-0.26*	-0.43*	-0.44*	-0.53*	-0.64*	-0.65*	-1.09*	-1.27*	-1.56*	-1.79*	-	-	-	-	-	-	-	-
Free Cashflow	46.0%	16,399	11,229	-6,931	-16,666	-11,127	-16,665	-16,770	-28,855	-37,141	-16,201	-36,737	-35,800	-35,817	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-5.7%	329	349	343	341	348	301	297	308	276	239	233	236	208	190	192	211	127	138	143	78.00	89.00
Current Assets	-6.1%	257	274	266	264	270	224	223	240	209	175	171	177	154	140	143	165	86.00	97.00	104	38.00	45.00
Cash Equivalents	-30.8%	51.00	74.00	63.00	69.00	87.00	35.00	52.00	70.00	51.00	34.00	42.00	62.00	56.00	60.00	76.00	101	27.00	48.00	74.00	17.00	27.00
Inventory	6.0%	173	163	162	164	163	163	146	139	125	114	100	94.00	82.00	70.00	56.00	52.00	53.00	40.00	24.00	18.00	19.00
Net PPE	-1.8%	54.00	55.00	56.00	57.00	58.00	57.00	55.00	53.00	51.00	48.00	46.00	44.00	42.00	40.00	37.00	35.00	32.00	31.00	29.00	30.00	30.00
Goodwill	0%	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
Liabilities	-1.8%	194	198	196	195	196	200	183	181	135	136	121	123	119	119	115	114	101	102	96.00	68.00	69.00
Current Liabilities	19.0%	50.00	42.00	42.00	37.00	39.00	44.00	28.00	32.00	30.00	32.00	18.00	21.00	20.00	16.00	13.00	14.00	14.00	15.00	10.00	8.00	10.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.00
Shareholder's Equity	-10.7%	135	151	147	146	152	100	114	127	141	103	112	113	88.00	71.00	77.00	96.00	26.00	36.00	47.00	10.00	20.00
Retained Earnings	-3.6%	-506	-488	-491	-484	-478	-465	-450	-437	-412	-395	-377	-358	-340	-321	-304	-283	-264	-254	-242	-229	-216
Additional Paid-In Capital	0.2%	641	640	638	630	630	566	565	564	553	498	489	471	429	392	381	380	291	290	290	240	236
Shares Outstanding	0.0%	226	226	225	222	222	196	196	196	140	134	127	116	105	-	-	-	-	-	-	-	-
Float	-	-	-	794	-	-	-	373	-	-	-	173	-	-	-	184	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	46.8%	17,596	11,985	-6,058	-14,722	-7,379	-13,284	-12,830	-26,013	-33,465	-13,412	-32,262	-33,229	-32,219	-23,852	-21,284	-24,646	-19,652	-23,630	-18,623	-14,287	-18,793
Share Based Compensation	3.0%	1,745	1,695	1,637	1,110	1,069	1,313	1,191	1,641	1,213	688	805	781	688	775	716	677	636	651	727	637	596
Cashflow From Investing	-86.0%	-1,407	-756	-872	-1,944	-3,748	-3,380	-3,940	-2,842	-3,675	-2,788	-4,475	-2,571	-3,598	-2,885	-4,168	-2,072	-1,594	-1,971	-135	-110	-819
Cashflow From Financing	-9488.1%	-38,993	415	240	-650	62,744	-843	-319	47,271	53,819	8,203	17,181	41,845	32,064	10,631	-1.69	101,203	-7.68	-7.56	75,841	4,177	-507*
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

ADMA Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]
REVENUES	$ 258,215	$ 154,080	$ 80,943
Cost of product revenue	169,273	118,815	79,770
Gross profit	88,942	35,265	1,173
OPERATING EXPENSES:
Research and development	3,300	3,614	3,646
Plasma center operating expenses	4,266	17,843	12,289
Amortization of intangible assets	724	715	715
Selling, general and administrative	59,020	52,458	42,897
Total operating expenses	67,310	74,630	59,547
INCOME (LOSS) FROM OPERATIONS	21,632	(39,365)	(58,374)
OTHER INCOME (EXPENSE):
Interest income	1,617	45	35
Interest expense	(25,027)	(19,279)	(13,057)
Loss on extinguishment of debt	(26,174)	(6,670)	0
Other expense	(287)	(635)	(252)
Other expense, net	(49,871)	(26,539)	(13,274)
NET LOSS	$ (28,239)	$ (65,904)	$ (71,648)
BASIC LOSS PER COMMON SHARE (in dollars per share)	$ (0.13)	$ (0.33)	$ (0.51)
DILUTED LOSS PER COMMON SHARE (in dollars per share)	$ (0.13)	$ (0.33)	$ (0.51)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic (in shares)	223,977,315	197,874,895	139,578,538
Diluted (in shares)	223,977,315	197,874,895	139,578,538

ADMA Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 51,352	$ 86,522
Accounts receivable, net	27,421	15,505
Inventories	172,906	163,280
Prepaid expenses and other current assets	5,334	5,095
Total current assets	257,013	270,402
Property and equipment, net	53,835	58,261
Intangible assets, net	499	1,013
Goodwill	3,530	3,530
Right-to-use assets	9,635	10,485
Deposits and other assets	4,670	4,770
TOTAL ASSETS	329,182	348,461
Current liabilities:
Accounts payable	15,660	13,229
Accrued expenses and other current liabilities	32,919	24,990
Current portion of deferred revenue	182	143
Current portion of lease obligations	1,045	905
Total current liabilities	49,806	39,267
Senior notes payable, net of discount	130,594	142,833
Deferred revenue, net of current portion	1,690	1,833
End of term fee	1,688	1,500
Lease obligations, net of current portion	9,779	10,704
Other non-current liabilities	419	350
TOTAL LIABILITIES	193,976	196,487
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding	0	0
Common Stock - voting, $0.0001 par value, 300,000,000 shares authorized, 226,063,032 and 221,816,930 shares issued and outstanding	23	22
Additional paid-in capital	641,439	629,969
Accumulated deficit	(506,256)	(478,017)
TOTAL STOCKHOLDERS' EQUITY	135,206	151,974
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 329,182	$ 348,461

About ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

CEO	Mr. Adam S. Grossman
WEBSITE	admabiologics.com
INDUSTRY	Biotechnology
EMPLOYEES	617

ADMA Biologics Inc Frequently Asked Questions

What is the ticker symbol for ADMA Biologics Inc? What does ADMA stand for in stocks?

ADMA is the stock ticker symbol of ADMA Biologics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ADMA Biologics Inc (ADMA)?

As of Mon Apr 15 2024, market cap of ADMA Biologics Inc is 1.36 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ADMA stock?

You can check ADMA's fair value in chart for subscribers.

What is the fair value of ADMA stock?

You can check ADMA's fair value in chart for subscribers. The fair value of ADMA Biologics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ADMA Biologics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ADMA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ADMA Biologics Inc a good stock to buy?

The fair value guage provides a quick view whether ADMA is over valued or under valued. Whether ADMA Biologics Inc is cheap or expensive depends on the assumptions which impact ADMA Biologics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ADMA.

What is ADMA Biologics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 15 2024, ADMA's PE ratio (Price to Earnings) is -48.33 and Price to Sales (PS) ratio is 5.29. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ADMA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ADMA Biologics Inc's stock?

In the past 10 years, ADMA Biologics Inc has provided -0.029 (multiply by 100 for percentage) rate of return.